Institute for Wealth Management’s Enliven Therapeutics ELVN Stock Holding History

Institute for Wealth Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53K	Buy	+30	New	+$1.27K	﹤0.01%	1624

Other funds holding ELVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Institute for Wealth Management's ELVN Position: Q2 2026 in Review

Institute for Wealth Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 30 shares worth $1.53K. The stake represents ﹤0.01% of the portfolio and ranks #1624 among its holdings.

53 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Institute for Wealth Management held 30 shares of Enliven Therapeutics worth $1.53K as of Q2 2026.
Enliven Therapeutics was a new Institute for Wealth Management position in Q2 2026.
Enliven Therapeutics made up ﹤0.01% of Institute for Wealth Management's portfolio in Q2 2026, its #1624 holding.
53 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Institute for Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.